Radiopharm Theranostics Limited American Depositary Shares (RADX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has a cash flow conversion efficiency ratio of -1.437x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.08 Million) by net assets ($22.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Radiopharm Theranostics Limited American for the company's overall valuation and market capitalisation.
Radiopharm Theranostics Limited American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2026)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their cash flow conversion efficiency. See Radiopharm Theranostics Limited American (RADX) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Andalan Perkasa Abadi Tbk PT
JK:NASA
|
0.000x |
|
Caesarstone Ltd
NASDAQ:CSTE
|
-0.066x |
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
-0.008x |
|
Khee San Bhd
KLSE:6203
|
0.138x |
|
Radiant Innovation
TWO:3373
|
0.014x |
|
BonTerra Resources Inc
V:BTR
|
0.894x |
|
NORTH PEAK RESOURCES LTD.
F:B9TN
|
-0.078x |
|
Control Bionics Ltd
AU:CBL
|
-0.559x |
Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026. View current stock price of Radiopharm Theranostics Limited American for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $22.32 Million | $-51.63 Million | -2.313x | -170.56% |
| 2025-06-30 | $42.87 Million | $-36.65 Million | -0.855x | -1.76% |
| 2024-06-30 | $27.35 Million | $-22.98 Million | -0.840x | -65.01% |
| 2023-06-30 | $45.58 Million | $-23.20 Million | -0.509x | -223.23% |
| 2022-06-30 | $62.96 Million | $-9.92 Million | -0.157x | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more